Literature DB >> 19063827

The problem of anaphylaxis and mastocytosis.

Ulrich R Müller1, Gabrielle Haeberli.   

Abstract

Mastocytosis is a rare disease characterized by an elevated whole body mast cell number. Anaphylaxis is a severe, generalized hypersensitivity reaction with rapid onset. The problem of anaphylaxis and mastocytosis is due to strongly increased mediator release from the elevated mast cell number during allergic reactions. This explains the much higher prevalence of anaphylaxis in mastocytosis than in the general population and its severe and sometimes fatal course. Because of the increased risk of anaphylaxis in mastocytosis, all patients with severe or recurrent anaphylaxis should be analyzed for underlying mastocytosis by estimation of baseline serum tryptase. If this is elevated, patients also should be tested via skin examination for cutaneous mastocytosis and with a bone marrow biopsy. All patients with mastocytosis and anaphylaxis must be instructed about avoiding the responsible elicitors and should carry an emergency kit with adrenaline for self-application. In mastocytosis patients with anaphylaxis due to Hymenoptera stings, venom immunotherapy is recommended for life.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19063827     DOI: 10.1007/s11882-009-0010-9

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  43 in total

1.  Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings.

Authors:  D Ludolph-Hauser; F Ruëff; C Fries; P Schöpf; B Przybilla
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

Review 2.  Treatment of cutaneous mastocytosis.

Authors:  Klaus Wolff
Journal:  Int Arch Allergy Immunol       Date:  2002-02       Impact factor: 2.749

Review 3.  Lessons for management of anaphylaxis from a study of fatal reactions.

Authors:  R S Pumphrey
Journal:  Clin Exp Allergy       Date:  2000-08       Impact factor: 5.018

Review 4.  Systemic mastocytosis.

Authors:  Cem Akin; Dean D Metcalfe
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

5.  Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes.

Authors:  Stefan Florian; Maria-Theresa Krauth; Ingrid Simonitsch-Klupp; Wolfgang R Sperr; Robert Fritsche-Polanz; Karoline Sonneck; Manuela Födinger; Hermine Agis; Alexandra Böhm; Friedrich Wimazal; Hans-Peter Horny; Peter Valent
Journal:  Int Arch Allergy Immunol       Date:  2005-02-17       Impact factor: 2.749

Review 6.  Epidemiology of life-threatening and lethal anaphylaxis: a review.

Authors:  D A Moneret-Vautrin; M Morisset; J Flabbee; E Beaudouin; G Kanny
Journal:  Allergy       Date:  2005-04       Impact factor: 13.146

Review 7.  Clinical and histopathological aspects of cutaneous mastocytosis.

Authors:  K Wolff; M Komar; P Petzelbauer
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

8.  Fatal anaphylactic sting reaction in a patient with mastocytosis.

Authors:  N Wagner; D Fritze; B Przybilla; M Hagedorn; F Ruëff
Journal:  Int Arch Allergy Immunol       Date:  2008-01-18       Impact factor: 2.749

9.  Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization.

Authors:  Kari Bohlke; Robert L Davis; Frank DeStefano; S Michael Marcy; M Miles Braun; Robert S Thompson
Journal:  J Allergy Clin Immunol       Date:  2004-03       Impact factor: 10.793

Review 10.  Mastocytosis: classification, diagnosis, and clinical presentation.

Authors:  Mariana C Castells
Journal:  Allergy Asthma Proc       Date:  2004 Jan-Feb       Impact factor: 2.587

View more
  8 in total

1.  Intestinal mast cell levels control severity of oral antigen-induced anaphylaxis in mice.

Authors:  Richard Ahrens; Heather Osterfeld; David Wu; Chun-Yu Chen; Muthuvel Arumugam; Katherine Groschwitz; Richard Strait; Yui-Hsi Wang; Fred D Finkelman; Simon P Hogan
Journal:  Am J Pathol       Date:  2012-02-07       Impact factor: 4.307

2.  Recent advances in mast cell clonality and anaphylaxis.

Authors:  Cem Akin
Journal:  F1000 Med Rep       Date:  2009-12-15

3.  Assessing anaphylactic risk? Consider mast cell clonality.

Authors:  Dean D Metcalfe; Lawrence B Schwartz
Journal:  J Allergy Clin Immunol       Date:  2009-03       Impact factor: 10.793

4.  Food-induced anaphylaxis: mast cells as modulators of anaphylactic severity.

Authors:  Simon P Hogan; Yui Hsi Wang; Richard Strait; Fred D Finkelman
Journal:  Semin Immunopathol       Date:  2012-08-02       Impact factor: 9.623

Review 5.  Critical care management of systemic mastocytosis: when every wasp is a killer bee.

Authors:  Hinke Y van der Weide; David J van Westerloo; Walter M van den Bergh
Journal:  Crit Care       Date:  2015-06-03       Impact factor: 9.097

Review 6.  Targeted Treatment Options in Mastocytosis.

Authors:  Mélanie Vaes; Fleur Samantha Benghiat; Olivier Hermine
Journal:  Front Med (Lausanne)       Date:  2017-07-20

7.  Vascular endothelial growth factors and angiopoietins as new players in mastocytosis.

Authors:  Simone Marcella; Angelica Petraroli; Mariantonia Braile; Roberta Parente; Anne Lise Ferrara; Maria Rosaria Galdiero; Luca Modestino; Leonardo Cristinziano; Francesca Wanda Rossi; Gilda Varricchi; Massimo Triggiani; Amato de Paulis; Giuseppe Spadaro; Stefania Loffredo
Journal:  Clin Exp Med       Date:  2021-03-09       Impact factor: 3.984

8.  SWATH-MS identification of CXCL7, LBP, TGFβ1 and PDGFRβ as novel biomarkers in human systemic mastocytosis.

Authors:  R L J Graham; A A McMullen; G Moore; N C Dempsey-Hibbert; B Myers; C Graham
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.